AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MAYNE PHARMA GROUP LTD

7.050

+0.0600.86%

Volume:305.48K

Turnover:2.15M

Market Cap:572.78M

PE:-4.30

High:7.095

Open:6.970

Low:6.960

Close:6.990

Loading ...

Overview Company News Filings

BRIEF-Sol-Gel And Mayne Pharma Announce The Purchase Of Epsolay And Twyneo In The U.S.

Sol-Gel- to Receive $16 Million During 2025

THOMSON REUTERS

Sol-Gel and Mayne Pharma Announce the Purchase of Epsolay® and Twyneo® in the U.S.

THOMSON REUTERS

Sol-Gel- Sgt-610 Phase Iii Trial Top-Line Results Expected Q4 2026

THOMSON REUTERS

BRIEF-Mayne Pharma Served With Legal Proceeding Filed Against One Of Its US Subsidiaries

Mayne Pharma Group Served With Legal Proceedings Against US Unit

MT Newswires Live

Mayne Pharma Group - Proceeding Is Brought by TherapeuticsMD, Inc. (Txmd) as Plaintiff

THOMSON REUTERS

Mayne Pharma - Served With Legal Proceeding Filed Against One of Its US Subsidiaries, Mayne Pharma Llc, in United States District Court

THOMSON REUTERS

Mayne Pharma Group - Proceeding Alleges Breach of Contract, Others

THOMSON REUTERS

Small companies, big swings and four future leaders that stand out

Wilsons Downgrades Mayne Pharma Group to Market-Weight from Overweight, Price Target is AU$7.40

MT Newswires Live

Mayne Pharma Group Ltd (MAYNF) (H1 2025) Earnings Call Highlights: Strong Growth in Women's ...

Mayne Pharma Group Posts Narrower Fiscal H1 Loss, Higher Revenue

MT Newswires Live

BRIEF-Mayne Pharma Posts H1 Gross Margin 53%

Mayne Pharma Group - Company Expects to Grow Underlying Ebitda in 2Hfy25 via Revenue Growth

THOMSON REUTERS

Mayne Pharma H1 Revenue AUD 94.3 Million

THOMSON REUTERS

Mayne Pharma H1 Gross Margin 53%

THOMSON REUTERS

Australian Shares Slide Despite Tech Stocks Rally; Mayne Pharma to be Acquired by Cosette in AU$672 Million Deal

MT Newswires Live

Mayne Pharma board backs $672 million takeover bid from Cosette Pharma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MYX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MYX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","market":"AU","secType":"STK","nameCN":"MAYNE PHARMA GROUP LTD","latestPrice":7.05,"timestamp":1744870320000,"preClose":6.99,"halted":0,"volume":305484,"delay":0,"nameEN":"MAYNE PHARMA GROUP LTD","floatShares":66962087,"shares":81245827,"eps":-1.638289,"marketStatus":"Not Yet Opened","change":0.06,"latestTime":"04-17 16:12:00 AEST","open":6.97,"high":7.095,"low":6.96,"amount":2151295,"amplitude":0.019313,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.638289,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":6.99,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0.3755947741211161,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","floatShares":66962087,"roa":"-0.61%","roe":"-23.75%","lyrEps":-2.188306,"volumeRatio":0.3755947741211161,"shares":81245827,"dividePrice":0,"high":7.095,"amplitude":0.019313,"preClose":6.99,"low":6.96,"week52Low":3.74,"pbRate":"1.28","psRate":"1.39","week52High":7.46,"institutionHeld":0,"latestPrice":7.05,"eps":-1.638289,"divideRate":0,"volume":305484,"delay":0,"ttmEps":-1.638289,"open":6.97,"prevYearClose":4.97,"prevWeekClose":7.05,"prevMonthClose":7.23,"prevQuarterClose":7.23,"fiveDayClose":7,"twentyDayClose":7.23,"sixtyDayClose":4.56},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MYX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528714045","title":"BRIEF-Sol-Gel And Mayne Pharma Announce The Purchase Of Epsolay And Twyneo In The U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2528714045","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528714045?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:49","pubTimestamp":1744894159,"startTime":"0","endTime":"0","summary":"BRIEF-Sol-Gel And Mayne Pharma Announce The Purchase Of Epsolay And Twyneo In The U.S.April 17 (Reuters) - Mayne Pharma Group Ltd MYX.AX:SOL-GEL AND MAYNE PHARMA ANNOUNCE THE PURCHASE OF EPSOLAY AND T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV1FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","SLGL"],"gpt_icon":0},{"id":"2528714955","title":"Sol-Gel- to Receive $16 Million During 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2528714955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528714955?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:42","pubTimestamp":1744893775,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV1FQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK4007","BK7096","BK7508","SLGL"],"gpt_icon":0},{"id":"2528714629","title":"Sol-Gel and Mayne Pharma Announce the Purchase of Epsolay® and Twyneo® in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2528714629","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528714629?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:42","pubTimestamp":1744893775,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV1FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK4007","BK7096","SLGL"],"gpt_icon":0},{"id":"2528149007","title":"Sol-Gel- Sgt-610 Phase Iii Trial Top-Line Results Expected Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2528149007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528149007?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:42","pubTimestamp":1744893775,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV1FQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","BK4007","MYX.AU","SLGL"],"gpt_icon":0},{"id":"2526573849","title":"BRIEF-Mayne Pharma Served With Legal Proceeding Filed Against One Of Its US Subsidiaries","url":"https://stock-news.laohu8.com/highlight/detail?id=2526573849","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526573849?lang=en_us&edition=fundamental","pubTime":"2025-04-11 09:28","pubTimestamp":1744334919,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Served With Legal Proceeding Filed Against One Of Its US SubsidiariesApril 11 (Reuters) - Mayne Pharma Group Ltd MYX.AX:SERVED WITH LEGAL PROCEEDING FILED AGAINST ONE OF ITS US SUBS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QO1T1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2526521776","title":"Mayne Pharma Group Served With Legal Proceedings Against US Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2526521776","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526521776?lang=en_us&edition=fundamental","pubTime":"2025-04-11 08:08","pubTimestamp":1744330111,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  said that it has been served with a legal proceeding filed in the US District Court of Delaware against its US unit, Mayne Pharma, according to a Friday filing with the Australian bourse.The lawsuit filed by US-based women's healthcare company TherapeuticsMD  alleges breach of contract, fraudulent inducement, and unjust enrichment related to the 2022 transaction agreement between the companies, the filing said.The company plans to vigorously defend the case, which it believes is without merit, the filing added.MYX also stated it had separate claims against TXMD, alleging damages exceeding TXMD's claims.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK7508","BK7096","MYX.AU","TXMD"],"gpt_icon":0},{"id":"2526526916","title":"Mayne Pharma Group - Proceeding Is Brought by TherapeuticsMD, Inc. (Txmd) as Plaintiff","url":"https://stock-news.laohu8.com/highlight/detail?id=2526526916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526526916?lang=en_us&edition=fundamental","pubTime":"2025-04-11 07:28","pubTimestamp":1744327682,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO1T1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2526526913","title":"Mayne Pharma - Served With Legal Proceeding Filed Against One of Its US Subsidiaries, Mayne Pharma Llc, in United States District Court","url":"https://stock-news.laohu8.com/highlight/detail?id=2526526913","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526526913?lang=en_us&edition=fundamental","pubTime":"2025-04-11 07:28","pubTimestamp":1744327682,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO1T1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2526152691","title":"Mayne Pharma Group -  Proceeding Alleges Breach of Contract, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2526152691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526152691?lang=en_us&edition=fundamental","pubTime":"2025-04-11 07:28","pubTimestamp":1744327682,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO1T1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2514831397","title":"Small companies, big swings and four future leaders that stand out","url":"https://stock-news.laohu8.com/highlight/detail?id=2514831397","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514831397?lang=en_us&edition=fundamental","pubTime":"2025-02-28 13:12","pubTimestamp":1740719546,"startTime":"0","endTime":"0","summary":"In our reporting season update, I talk to Jason Guthrie about another volatile reporting season in the small to mid-cap end of the ASX. As always there have been many winners and losers and I discuss the trends we are seeing, including margin pressures and a reckoning for some of the best performing companies and sectors of recent months. I also outline the performance of a some of IML’s key holdings including Mayne Pharma , oOh!Media , Integral Diagnostics  and Light & Wonder .So, it’s been very volatile, but I think if we look at the reporting season in totality, the key messages we can take away are that consumers are still fairly price-conscious and value-conscious, but it’s not diabolical in terms of how the consumer is performing. If you look at the revenue lines that many of the companies have reported this reporting season, that’s actually held up OK. Companies are growing their top line o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/small-companies-big-swings-and-four-future-leaders-that-stand-out","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/small-companies-big-swings-and-four-future-leaders-that-stand-out","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["OML.AU","LNW.AU","BK7078","BK7096","BK7124","BK7045","BK7052","SWM.AU","BK7508","MYX.AU","IDX.AU"],"gpt_icon":0},{"id":"2514873529","title":"Wilsons Downgrades Mayne Pharma Group to Market-Weight from Overweight, Price Target is AU$7.40","url":"https://stock-news.laohu8.com/highlight/detail?id=2514873529","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514873529?lang=en_us&edition=fundamental","pubTime":"2025-02-27 17:22","pubTimestamp":1740648162,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group (ASX:MYX) has an average rating of outperform and price targets ranging from AU$5.95 to AU$7.40, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MYX.AU"],"gpt_icon":0},{"id":"2514886705","title":"Mayne Pharma Group Ltd (MAYNF) (H1 2025) Earnings Call Highlights: Strong Growth in Women's ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2514886705","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514886705?lang=en_us&edition=fundamental","pubTime":"2025-02-26 17:00","pubTimestamp":1740560431,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Revenues increased by 13% to $213.1 million, driven by strong growth in the women's health segment.Gross margin expanded significantly to 61.4% from 56.3% in the prior corresponding period.Underlying EBITA rose by 288%, showcasing substantial improvement in profitability.Positive operating cash flow of $25.9 million from continued operations, a significant turnaround from a negative cash flow in the previous period.The women's health portfolio showed strong performance with revenues up 30% and direct contribution up 117%.Revenue from dermatology showed only modest growth of 1%, with competition affecting sales of certain products.International segment's direct contribution declined due to timing effects of shipments and production schedules.Despite improvements, the company faces ongoing challenges with legacy inventory returns affecting revenue in the women's health segment.A:  The turn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mayne-pharma-group-ltd-maynf-090031789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["MYX.AU","MAYNF"],"gpt_icon":0},{"id":"2514020769","title":"Mayne Pharma Group Posts Narrower Fiscal H1 Loss, Higher Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2514020769","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514020769?lang=en_us&edition=fundamental","pubTime":"2025-02-26 10:06","pubTimestamp":1740535587,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  reported Wednesday a fiscal first-half loss of AU$0.323 per diluted share, narrowing from AU$0.878 per diluted share a year earlier.Revenue for the six months ended Dec. 31, 2024, was AU$213.1 million, up 13% from AU$187.9 million a year earlier.The company said it expects to grow underlying earnings before interest, taxes, depreciation, and amortization in the second fiscal half via revenue growth and cost leverage.The firm did not declare a dividend for the reported half-year.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MYX.AU"],"gpt_icon":0},{"id":"2514022114","title":"BRIEF-Mayne Pharma Posts H1 Gross Margin 53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514022114","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514022114?lang=en_us&edition=fundamental","pubTime":"2025-02-26 09:30","pubTimestamp":1740533428,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Posts H1 Gross Margin 53%Feb 26  - Mayne Pharma Group Ltd MYX.AX:H1 GROSS MARGIN 53%H1 REVENUE AUD 94.3 MILLIONH1 GROSS PROFIT AUD 76.9 MILLIONH1 ADJUSTED EBITDA AUD 31 MILLIONCOMPANY EXPECTS TO GROW UNDERLYING EBITDA IN 2HFY25 VIA REVENUE GROWTHFurther company coverage: MYX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nPLX92B737:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2514408042","title":"Mayne Pharma Group - Company Expects to Grow Underlying Ebitda in 2Hfy25 via Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2514408042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514408042?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:54","pubTimestamp":1740520494,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nPLX92B737:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2514042109","title":"Mayne Pharma H1 Revenue AUD 94.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514042109","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514042109?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:54","pubTimestamp":1740520494,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nPLX92B737:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2514004217","title":"Mayne Pharma H1 Gross Margin 53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514004217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514004217?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:54","pubTimestamp":1740520494,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nPLX92B737:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2513239035","title":"Australian Shares Slide Despite Tech Stocks Rally; Mayne Pharma to be Acquired by Cosette in AU$672 Million Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2513239035","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513239035?lang=en_us&edition=fundamental","pubTime":"2025-02-21 14:17","pubTimestamp":1740118679,"startTime":"0","endTime":"0","summary":"Australian shares slid on Friday's close despite gains from Asian markets fuelled by the rise in tech stocks as Chinese tech firm Alibaba Group Holdings' revenue beat estimates.The S&P/ASX 200 Index f","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7002","BK4137","BK7096","DHG.AU","QBE.AU","XAO.AU","LU1303367103.USD","LU2098885051.SGD","LU1815336091.USD","RBA","BK7503","XKO.AU","BK7034","MYX.AU","LU0757428866.USD","XJO.AU","BK7508"],"gpt_icon":0},{"id":"2513378235","title":"Mayne Pharma board backs $672 million takeover bid from Cosette Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2513378235","media":"Small Caps","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513378235?lang=en_us&edition=fundamental","pubTime":"2025-02-21 10:08","pubTimestamp":1740103689,"startTime":"0","endTime":"0","summary":"Mayne Pharma  has received a takeover offer at a price of $7.40 per share from US-based pharmaceutical company Cosette Pharma, valuing the company at $672 million.Cosette has a portfolio of products in women’s health and dermatology and a long history of manufacturing complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories.The US-based firm is backed by healthcare-focused private equity firm Avista Healthcare Partners and funds controlled by private markets investment management firm Hamilton Lane.Mayne Pharma chief executive officer Shawn Patrick O’Brien said this was a pivotal moment in Mayne’s journey to improve patient access to life-enhancing medications.“Attracting an offer from a strategic buyer who is active in the US dermatology and women’s health markets, such as Cosette, reflects the excellent work our teams have been doing to strengthen our company over the last year and more,” chair Frank Condella added.The Mayne Pharma board has ","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Mayne-Pharma-ASX-MYX-Cosette-Pharmaceuticals-takeover-bid.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Mayne-Pharma-ASX-MYX-Cosette-Pharmaceuticals-takeover-bid.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/mayne-pharma-board-backs-takeover-bid-cosette/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MYX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-23","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724371200000,"name":null,"time":"","dateTimestamp":1724335200000,"actualEps":null},{"date":"2024-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708902000000,"name":null,"time":"","dateTimestamp":1708866000000,"actualEps":null},{"date":"2023-08-31","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693440000000,"name":null,"time":"","dateTimestamp":1693404000000,"actualEps":null},{"date":"2023-02-28","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1677538800000,"name":null,"time":"","dateTimestamp":1677502800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MYX.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-01-18","recordDate":"2023-01-19","paymentDate":"2023-01-27","value":0.038,"currency":"AUD"}]}}